H.C. Wainwright Reiterates Buy Rating on Innate Pharma S.A. (IPHA)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $11.50 price target on Innate Pharma S.A. (NASDAQ: IPHA).

The analyst commented: "On September 12, Innate reported 1H24 financial results and held a conference call. For 1H24, Innate reported revenues of €12.3M and a net loss of €0.31 per share. For 2024, we project revenues of approximately €22M and a net loss of €0.67 per share. Innate exited 1H24 with cash and cash equivalents of €102M, which we believe is sufficient fund to support operations until the end of 2025. We maintain our Buy rating on Innate and our 12-month price target of $11.50."

For an analyst ratings summary and ratings history on Innate Pharma S.A. click here. For more ratings news on Innate Pharma S.A. click here.

Shares of Innate Pharma S.A. closed at $2.28 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Goldman Sachs Upgrades Plains All American (PAA) to Neutral
• RBC Capital on Veeva Systems (VEEV) Amid After Hours Selloff on Earnings: 'we are surprised to see shares trade down'